豐原藥業(000153.SZ)擬斥1億元參設創投基金 投向醫藥健康領域
格隆匯11月29日丨豐原藥業(000153.SZ)公佈,為拓展醫藥健康產業投資,提升公司綜合競爭力,公司擬與北京首都科技發展集團投資管理有限公司、北京市科技創新基金(有限合夥)、中關村科技園區海淀園創業服務中心、北京九城投資有限公司、北京首都科技發展集團有限公司及景隆資產管理(北京)有限公司共同發起設立“北京首發展天璣創業投資中心(有限合夥)”(暫定名,“創投基金”)。公司作為有限合夥人擬認繳創投基金出資額人民幣1億元,佔創投基金全體合夥人認繳出資總額的10%。
北京首發展天璣創業投資中心(有限合夥)基金投向:醫藥健康領域。
此次發起設立創投基金有利於公司充分利用專業投資機構的管理經驗及投資資源,進一步開拓投資渠道,發掘優質標的企業,增強持續盈利能力,提升整體競爭實力和投資管理水平。
公司此次對外投資的資金全部來源於公司自有資金,不涉及募集資金,且投資期限較長,公司作為合夥企業的有限合夥人,若合夥企業出現虧損,則需以出資額為限承擔虧損責任,北京首都科技發展集團投資管理有限公司作為合夥企業的普通合夥人,對合夥企業債務承擔無限連帶責任。此次交易對公司本年度的財務狀況和經營成果不會產生重大影響,對公司未來財務狀況的影響將根據投資項目具體投資收益而定。公司在基金擬投資標的的表決中不享有一票否決權,此次對外投資不會導致公司合併報表範圍發生變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.